Profhilo
Profhilo Body for ageing hands: what does the evidence support?
A small single-centre study reported changes in hand skin measurements after Profhilo Body, but it had no comparison group and cannot show how much visible improvement an individual will notice.
Ageing hands involve more than skin hydration
The backs of the hands change through sun exposure, repeated washing, loss of skin elasticity and thinning of the tissues beneath the skin. Veins and tendons may become more visible, while pigmentation, roughness and laxity can develop together. These features have different causes, so one injectable cannot be expected to correct all of them.
Profhilo Body contains hybrid complexes of high- and low-molecular-weight hyaluronic acid. For the hands, it has been studied as a treatment for skin roughness and laxity rather than as a conventional filler for replacing substantial volume. It should not be assumed to hide prominent veins, remove sun spots or rebuild lost fat.
What did the hand study involve?
A single-centre study included 46 adults aged 38 to 65 who requested hand rejuvenation. Participants received two Profhilo Body sessions and were assessed at four and 16 weeks. Researchers used photographs and measurements of skin roughness, laxity, resistance to pinching, density and elastic behaviour, together with a participant questionnaire.
The 2026 systematic review reported improvement in several instrumental measures. Elastic behaviour improved at 16 weeks, while some roughness and depth measurements changed at four or 16 weeks. The associated trial registry describes an open-label, industry-sponsored study without randomisation, blinding or a separate control group.
Why the findings remain uncertain
Without an untreated hand or alternative-treatment comparison, the study cannot separate the procedure’s effect from normal variation, skincare changes, seasonal humidity, expectations or measurement variability. Everyone knew treatment had been given. Follow-up lasted four months, so the study does not establish how long any improvement lasts or what maintenance schedule is proportionate.
The hand study came from one centre, and the wider systematic review was funded by the product manufacturer; several review authors were company employees. Patient satisfaction across the included studies was measured with non-validated questionnaires. These factors do not erase the results, but they reduce certainty and underline the need for independent, controlled trials with longer follow-up.
A measured change may not equal a visible transformation
A statistically significant change in elasticity or surface roughness does not tell us whether another person will see a meaningful difference. The study did not prove that treatment reverses every sign of hand ageing. Pigment, precancerous sun damage, eczema, prominent veins, tendon visibility and volume loss each need separate assessment and may require different advice—or no cosmetic procedure.
Consultation should define the main concern and compare realistic options. Daily broad-spectrum sun protection, moisturising and irritant avoidance may still be important. Suspicious, changing, scaly, bleeding or non-healing lesions require medical assessment rather than camouflage with an injectable treatment.
Downtime and possible adverse effects
Temporary tenderness, redness, swelling, bruising, itching, small bumps or localised haematoma may follow injections. The systematic review found that reported injection-site effects were usually mild and settled within a few days, but small studies cannot reliably detect rare complications. Hand swelling may also affect comfort and normal activities during recovery.
Increasing pain, spreading redness or heat, discharge, fever, unusual pale or mottled skin, marked swelling, numbness or reduced finger movement needs prompt clinical assessment. Any injectable procedure carries infection and vascular risk, and the anatomy and blood supply of the hands require an appropriately trained practitioner and clear emergency arrangements.
Suitability must be individual
Medical conditions, medicines—including those affecting bleeding—previous reactions, allergies, pregnancy or breastfeeding, active dermatitis or infection and planned hand procedures must be reviewed. The exact product and its instructions matter. Somebody with very thin tissue, significant volume loss or primarily pigmented change may not be a suitable candidate for this approach.
GMC guidance requires honest discussion of the evidence, uncertainties, risks, alternatives and follow-up before a cosmetic intervention. Current evidence suggests possible improvement in selected skin-quality measurements, not a guaranteed younger-looking hand. A careful consultation should decide whether the likely subtle benefit justifies the injections, downtime and cost for that individual.